Comparison · NCT01753856-sae
Teriparatide vs Denosumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Teriparatide vs Denosumab: serious adverse events. Trial comparisons, record NCT01753856-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01753856-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0606 | 0.0168 | 0.196 | wilson | |
| Risk in group 2 | 0.0556 | 0.0154 | 0.181 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00505 | -0.128 | 0.146 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.09 | 0.163 | 7.31 | log | |
| Odds ratio, group 1 over group 2 | 1.1 | 0.146 | 8.26 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Teriparatide than on Denosumab | 198 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Teriparatide | Teriparatide: 20-µg SC injection once daily for 6 months.~DEM: 150-mg tablets administered orally, on the following days, 18 days prior to randomization:~* Days 1, 2, 3, 16, 17, and 18: 150 mg DEM every 6 hours.~* Days 4 through 15: DEM was not administered.~TET: 250-mg capsules administered orally on the following days, 22 days prior to biopsy procedure:~* Days 1, 2, 3, 16, 17, and 18: 250 mg TET every 6 hours.~* Days 4 through 15: TET was not administered.~Calcium Supplements: Approximately 1000 mg/day administered orally for 6 months.~Vitamin D Supplements: Approximately 800 to 1200 IU/day administered orally for 6 months. | 2 | 33 | EG000 |
| Group 2 | Denosumab | Denosumab: A single 60-mg SC injection.~DEM: 150-mg tablets administered orally on the following days, 18 days prior to randomization:~* Days 1, 2, 3, 16, 17, and 18: 150 mg DEM every 6 hours.~* Days 4 through 15: DEM was not administered.~TET: 250-mg capsules administered orally on the following days, 22 days prior to biopsy procedure:~* Days 1, 2, 3, 16, 17, and 18: 250 mg TET every 6 hours.~* Days 4 through 15: TET was not administered.~Calcium Supplements: Approximately 1000 mg/day administered orally for 6 months.~Vitamin D Supplements: Approximately 800 to 1200 IU/day administered orally for 6 months. | 2 | 36 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
- NCT number
- NCT01753856
- Phases
- PHASE4
- Conditions
- Osteoporosis
- Interventions
- Teriparatide, Denosumab, Demeclocycline, Tetracycline, Calcium Supplement, Vitamin D
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2015-10-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01753856?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01753856-sae